Actively Recruiting
A Prospective Study to Evaluate Clinical Outcomes in Patients With Anti-leucine-rich Glioma-inactivated 1 Encephalitis
Led by Shen Chun-Hong · Updated on 2025-08-27
60
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis, a type of autoimmune encephalitis that causes seizures, memory loss, behavior changes, sleep problems, and low sodium levels. This condition is the second most common autoimmune encephalitis after anti-NMDAR encephalitis. The study aims to prospectively investigate the clinical outcomes and factors associated with anti-LGI1 encephalitis, as previous prospective studies on this topic are limited. This observational study will enroll newly diagnosed patients during the acute stage before treatment. Participants will undergo various routine and advanced tests, including blood and cerebrospinal fluid analyses, brain MRI with multiple imaging techniques, EEG or continuous video EEG, PET scans, and neuropsychological assessments. These evaluations will be performed at the acute stage and throughout follow-up to analyze clinical outcomes and related factors. Participants will be monitored over time with assessments focused on seizure outcomes, clinical severity, recovery, and recurrence rates at one and two years. Secondary measures include memory tests and brain volume analysis. The study involves comprehensive testing and follow-up evaluations to better understand the disease progression and outcomes in patients with anti-LGI1 encephalitis.
CONDITIONS
Brief Title
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meet the 2016 consensus diagnostic criteria for anti-LGI1 encephalitis
- Newly diagnosed and in the acute stage before study enrollment
- Sign the informed consent form
You will not qualify if you...
- History of epilepsy, stroke, brain trauma, or other nervous system diseases before encephalitis onset
- Presence of coexisting antibodies such as anti-CASPR2 antibody
- Lost to follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Acute stage before enrollment
Participants undergo routine and advanced examinations including blood and cerebrospinal fluid tests, multimodal brain MRI, EEG or continuous video-EEG, PET, neuropsychological tests, and other paraclinical assessments.
1 to 2 visits depending on assessments
Duration - Up to 2 years
Participants are monitored over time to evaluate clinical outcomes such as seizure outcomes, clinical severity and recovery, incidence of recurrence, memory assessments, and brain volume changes.
Periodic visits at 1 year and 2 year follow-ups
Trial Site Locations
Total: 1 location
1
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
M
Mei-Ping Ding
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here